VivoSeq
Other

Partial Response

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Partial Response is an early-stage landscape with 0 programs across 1 company. The most active players are AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

40/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Completed2 · 40%
Terminated2 · 40%
Unknown status1 · 20%

Clinical Trials

Trial Activity

TAF Switch in F3/4 CHB pt With Partial Response to NUC (ESTAB-AFPVR)
Unknown status·KKaohsiung Medical University Chung-Ho Memorial Hospital·Phase 4·NCT03798119·80 enrolled
Efficacy of Pimozide Augmentation for Clozapine Partial Response
Completed·YYale University·Phase 2·NCT00374244·28 enrolled
Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin
Terminated·KKadmon Corporation, LLC·Phase 4·NCT00456248·5 enrolled
Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT01005251·661 enrolled
Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy
Terminated·AstraZeneca logoAstraZeneca·Phase 4·NCT01128114·32 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)